RE:Another new articleStill an overall positive article reguarding Ventipoints technology fiveniner. Thnx.
The commercial application of this technology is the Ventripoint imaging system, which was evaluated in a multicenter clinical trial in PAH patients in comparison to CMR. Though full results of the study have not been published to date, the Ventripoint system reportedly generated similar volumes to Figure 2: Definition of anatomic points from standard 2D-TTE views using the Ventripoint system (Panels A–D) to generate 3D reconstruction of the RV (Panel E) in both diastole and systole (Panel F). Advances in Pulmonary Hypertension Volume 14, Number 1; 2015 31 CMR performed within 24 hours of the Ventripoint echocardiogram, and based on the results of this trial data, the Ventripoint system has been approved by the United States Food and Drug Administration for RV quantification. To date there has been relatively little clinical experience with this technology in PAH patients outside of the clinical trial arena, but this system certainly has the potential to significantly enhance routine echocardiographic assessment of RV volume and EF. Using the Ventripoint technology might be a less costly secondary endpoint in future PAH clinical trials.